A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

NCT07015762 | Recruiting Phase 1

• 1 other identifier: CIBI3002T002
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of IBI3002 in participants with moderate to severe atopic dermatitis (AD). The study plans to enroll patients with moderate to severe AD who have a poor response to topical treatment or who are not suitable for topical treatments. It aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, PD characteristics, and changes in clinical characteristics of these participants receiving multiple doses of IBI3002. The entire study includes the screening period (4 weeks before dosing), the dosing period (12 weeks), and the safety follow-up period (8 weeks). The study plans to enroll 9 to 27 participants with moderate to severe AD, who will be randomly assigned in a 1:1:1 ratio to the following 3 cohorts to receive subcutaneous injection of the corresponding dose of IBI3002 or a matching volume of placebo. Investigators and participants remain blind within the same cohort. Cohort 1: 150mg SC (IBI3002: placebo=2 :1); Cohort 2: 300mg SC (IBI3002: placebo=2 :1); Cohort 3: 600mg SC( IBI3002: placebo=2 :1); The participants need to be observed at the study site for 3 hours after each dose and are allowed to leave after investigators determine no safety risk.

Conditions

Atopic Dermatitis

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and tolerability of multiple doses of IBI3002 in Atopic Dermatitis patients.

  The incidence of Adverse events (AE) and Serious Adverse events (SAE) in participants with AD after multiple doses of IBI3002;

  Baseline to Week 20

Secondary Outcomes (3)

• To evaluate the PK parameters of IBI3002 in participants with AD;

  Baseline to Week 20

• To evaluate the PK parameters of IBI3002 in participants with AD;

  Baseline to Week 20

• To evaluate the PK parameters of IBI3002 in participants with AD;

  Baseline to Week 20

Study Arms (6)

Placebo 4ml SC

PLACEBO COMPARATOR

Participants with AD will receive Placebo 4ml SC

Drug: Placebo

IBI3002 300mg SC

EXPERIMENTAL

Participants with AD will receive IBI3002 300mg SC

Drug: IBI3002

IBI3002 600mg SC

EXPERIMENTAL

Participants with AD will receive IBI3002 600mg SC

Drug: IBI3002

Placebo 2ml SC

PLACEBO COMPARATOR

Participants with AD will receive Placebo 2ml SC

Drug: Placebo

Placebo 1ml SC

PLACEBO COMPARATOR

Participants with AD will receive Placebo 1ml SC

Drug: Placebo

IBI3002 150mg SC

EXPERIMENTAL

Participants with AD will receive IBI3002 150mg SC

Drug: IBI3002

Interventions

IBI3002 DRUG

Participants with AD will receive IBI3002 at the corresponding dose and dosing interval.

IBI3002 150mg SC; IBI3002 300mg SC; IBI3002 600mg SC

Placebo DRUG

Participants with AD will receive placebo at the corresponding volume and dosing interval.

Placebo 1ml SC; Placebo 2ml SC; Placebo 4ml SC

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Between 18 and 65 years.
• Weight ≥40kg.
• Meet the diagnostic criteria of the Hannifin \& Rajka criteria, and have been diagnosed with AD for ≥12 months at screening. If determined by Investigators, previous diagnostic terms like "dermatitis" and "eczema" are also acceptable.
• Have an Eczema area and severity index (EASI) score ≥16, the Investigator´s Global Assessment score ≥3, and the involved Body Surface Area (BSA) ≥10% at screening and randomization.

You may not qualify if:

• Having any disease that have an impact on the participant's own safety or participation in the study. Including but not limited to mental disorders, diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system or metabolic system, in the opinion of Investigator.
• Participants with a known history of active tuberculosis or clinically suspected manifestations of tuberculosis (including but not limited to pulmonary tuberculosis, lymph node tuberculosis, tuberculous pleurisy, etc.); Or chest imaging suggests the existence of suspected evidence of tuberculosis; Or there is any other clinical evidence of latent tuberculosis. Those with positive T-SPOT.TB need to receive preventive anti-tuberculosis treatment from 4 weeks before the first dose until the end of the study. If the participant is judged by Investigator to be intolerant to preventive anti-tuberculosis treatment, they should not be included in the study either.
• A history of malignant tumors, except for resected or cured localized basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin.
• The peripheral blood white blood cells or neutrophils are lower than the lower limit of the normal value, at screening or randomization.
• The co-existing of any other skin comorbidities that may interfere with the assessment related to AD, in the opinion of Investigators.
• The above information is not intended to contain all considerations relevant to a participant's potential participation in this trial.

Sponsors & Collaborators

• The First Affiliated Hospital of Soochow University: lead
• Innovent Biologics (Suzhou) Co. Ltd.: collaborator

Study Sites (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215000, China

RECRUITING

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Wensheng Zang

CONTACT

15210342569; wensheng.zang@innoventbio.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2025
• First Posted: June 11, 2025
• Study Start: July 14, 2025
• Primary Completion (Estimated): May 20, 2026
• Study Completion (Estimated): May 20, 2026
• Last Updated: August 7, 2025

Record last verified: 2025-08

Locations

CN (1)